Novartis puts the Development of two Anti-Aging Drugs in American Hands
PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping…
PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping…
A new report listing the top drug launches this year reveals the strong performance of…
Novartis has announced excellent results for 2016. Could its strong focus on biotech be the…
Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that…
The new year comes with uncertainty over the future of the biotech industry, whose finance…
What are the most impressive advances in medical biotechnology this year? From cancer to peanut…
Juno’s JCAR015 study came to a halt for the second time this year after two…
Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are…
Today marks an inflection point in the future of medicine: both parties fighting for the…
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's…
GSK is banishing concerns about its health with a BLA submission for Shingrix, which has…
Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster.…